CN108079284A - 一种提高母猪生产性能的药物、其制备方法及应用 - Google Patents
一种提高母猪生产性能的药物、其制备方法及应用 Download PDFInfo
- Publication number
- CN108079284A CN108079284A CN201711391548.3A CN201711391548A CN108079284A CN 108079284 A CN108079284 A CN 108079284A CN 201711391548 A CN201711391548 A CN 201711391548A CN 108079284 A CN108079284 A CN 108079284A
- Authority
- CN
- China
- Prior art keywords
- parts
- vitamin
- sow
- drug
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940079593 drug Drugs 0.000 title claims abstract description 93
- 239000003814 drug Substances 0.000 title claims abstract description 93
- 238000002360 preparation method Methods 0.000 title claims abstract description 63
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 48
- 239000000419 plant extract Substances 0.000 claims abstract description 46
- 102000004190 Enzymes Human genes 0.000 claims abstract description 41
- 108090000790 Enzymes Proteins 0.000 claims abstract description 41
- 150000001413 amino acids Chemical class 0.000 claims abstract description 36
- 239000006041 probiotic Substances 0.000 claims abstract description 36
- 235000018291 probiotics Nutrition 0.000 claims abstract description 36
- 229940088594 vitamin Drugs 0.000 claims abstract description 36
- 239000011782 vitamin Substances 0.000 claims abstract description 36
- 229930003231 vitamin Natural products 0.000 claims abstract description 35
- 235000013343 vitamin Nutrition 0.000 claims abstract description 35
- 150000003722 vitamin derivatives Chemical class 0.000 claims abstract description 35
- 235000002917 Fraxinus ornus Nutrition 0.000 claims abstract description 22
- 230000006651 lactation Effects 0.000 claims abstract description 13
- 229940088598 enzyme Drugs 0.000 claims description 40
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 32
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 32
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 claims description 30
- 244000182067 Fraxinus ornus Species 0.000 claims description 21
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 17
- 239000004472 Lysine Substances 0.000 claims description 17
- 229930182817 methionine Natural products 0.000 claims description 17
- 244000063299 Bacillus subtilis Species 0.000 claims description 16
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 16
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 claims description 16
- 239000009636 Huang Qi Substances 0.000 claims description 16
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 16
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 16
- 241000207925 Leonurus Species 0.000 claims description 16
- 235000000802 Leonurus cardiaca ssp. villosus Nutrition 0.000 claims description 16
- 108091005804 Peptidases Proteins 0.000 claims description 16
- 239000004365 Protease Substances 0.000 claims description 16
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 16
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 16
- 244000178320 Vaccaria pyramidata Species 0.000 claims description 16
- 235000010587 Vaccaria pyramidata Nutrition 0.000 claims description 16
- 229930003427 Vitamin E Natural products 0.000 claims description 16
- 239000011616 biotin Substances 0.000 claims description 16
- 229960002685 biotin Drugs 0.000 claims description 16
- 235000020958 biotin Nutrition 0.000 claims description 16
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 16
- 239000011647 vitamin D3 Substances 0.000 claims description 16
- 229940046009 vitamin E Drugs 0.000 claims description 16
- 235000019165 vitamin E Nutrition 0.000 claims description 16
- 239000011709 vitamin E Substances 0.000 claims description 16
- 239000004382 Amylase Substances 0.000 claims description 15
- 102000013142 Amylases Human genes 0.000 claims description 15
- 108010065511 Amylases Proteins 0.000 claims description 15
- 241000194108 Bacillus licheniformis Species 0.000 claims description 15
- 101710130006 Beta-glucanase Proteins 0.000 claims description 15
- 108010059892 Cellulase Proteins 0.000 claims description 15
- 235000001809 DL-alpha-tocopherylacetate Nutrition 0.000 claims description 15
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 15
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 15
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 15
- 235000019418 amylase Nutrition 0.000 claims description 15
- 229940106157 cellulase Drugs 0.000 claims description 15
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 15
- 229960000342 retinol acetate Drugs 0.000 claims description 15
- 235000019173 retinyl acetate Nutrition 0.000 claims description 15
- 239000011770 retinyl acetate Substances 0.000 claims description 15
- 239000004474 valine Substances 0.000 claims description 15
- 239000011716 vitamin B2 Substances 0.000 claims description 15
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 15
- 241000235342 Saccharomycetes Species 0.000 claims description 14
- 238000002156 mixing Methods 0.000 claims description 13
- 230000012010 growth Effects 0.000 claims description 11
- 239000000654 additive Substances 0.000 claims description 7
- 230000000996 additive effect Effects 0.000 claims description 7
- 238000000605 extraction Methods 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 239000003643 water by type Substances 0.000 claims description 6
- 238000005303 weighing Methods 0.000 claims description 4
- 239000000706 filtrate Substances 0.000 claims description 3
- 238000004904 shortening Methods 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims 5
- 235000009508 confectionery Nutrition 0.000 claims 1
- 235000013336 milk Nutrition 0.000 abstract description 11
- 239000008267 milk Substances 0.000 abstract description 11
- 210000004080 milk Anatomy 0.000 abstract description 11
- 230000016087 ovulation Effects 0.000 abstract description 4
- 230000036541 health Effects 0.000 abstract description 3
- 238000011084 recovery Methods 0.000 abstract description 3
- 230000004083 survival effect Effects 0.000 abstract description 3
- 238000001647 drug administration Methods 0.000 abstract description 2
- 230000023247 mammary gland development Effects 0.000 abstract description 2
- 239000000273 veterinary drug Substances 0.000 abstract description 2
- 241001289435 Astragalus brachycalyx Species 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 37
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 22
- 241000282898 Sus scrofa Species 0.000 description 18
- 239000000203 mixture Substances 0.000 description 17
- 238000009395 breeding Methods 0.000 description 15
- 230000001488 breeding effect Effects 0.000 description 15
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 229960003646 lysine Drugs 0.000 description 12
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 11
- 230000012173 estrus Effects 0.000 description 11
- 239000011724 folic acid Substances 0.000 description 11
- 229960000304 folic acid Drugs 0.000 description 11
- 235000019152 folic acid Nutrition 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 210000001835 viscera Anatomy 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 230000036039 immunity Effects 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 210000002381 plasma Anatomy 0.000 description 6
- 230000035935 pregnancy Effects 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 239000011573 trace mineral Substances 0.000 description 6
- 235000013619 trace mineral Nutrition 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 5
- 210000000481 breast Anatomy 0.000 description 5
- 238000007726 management method Methods 0.000 description 5
- 230000000474 nursing effect Effects 0.000 description 5
- 230000035764 nutrition Effects 0.000 description 5
- 235000016709 nutrition Nutrition 0.000 description 5
- 241000282887 Suidae Species 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 235000014590 basal diet Nutrition 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 230000005906 menstruation Effects 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 230000001850 reproductive effect Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000003022 colostrum Anatomy 0.000 description 3
- 235000021277 colostrum Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 230000001228 trophic effect Effects 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- MJVAVZPDRWSRRC-UHFFFAOYSA-N Menadione Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1 MJVAVZPDRWSRRC-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 235000019742 Vitamins premix Nutrition 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- -1 nicotinate chromium Chemical compound 0.000 description 2
- 210000002394 ovarian follicle Anatomy 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000003307 slaughter Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- BZVFZBYIWNIHHL-WCCKRBBISA-N (2s)-2-amino-4-methylsulfanylbutanoic acid;manganese Chemical compound [Mn].CSCC[C@H](N)C(O)=O BZVFZBYIWNIHHL-WCCKRBBISA-N 0.000 description 1
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 241000213006 Angelica dahurica Species 0.000 description 1
- 101100492584 Caenorhabditis elegans ast-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 235000019743 Choline chloride Nutrition 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- PMVSDNDAUGGCCE-TYYBGVCCSA-L Ferrous fumarate Chemical compound [Fe+2].[O-]C(=O)\C=C\C([O-])=O PMVSDNDAUGGCCE-TYYBGVCCSA-L 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 206010021703 Indifference Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 description 1
- 108010070158 Lactose synthase Proteins 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- CANRESZKMUPMAE-UHFFFAOYSA-L Zinc lactate Chemical compound [Zn+2].CC(O)C([O-])=O.CC(O)C([O-])=O CANRESZKMUPMAE-UHFFFAOYSA-L 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 1
- 229960003178 choline chloride Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- VVYPIVJZLVJPGU-UHFFFAOYSA-L copper;2-aminoacetate Chemical compound [Cu+2].NCC([O-])=O.NCC([O-])=O VVYPIVJZLVJPGU-UHFFFAOYSA-L 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 229940011405 cupric glycinate Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 235000002332 ferrous fumarate Nutrition 0.000 description 1
- 239000011773 ferrous fumarate Substances 0.000 description 1
- 229960000225 ferrous fumarate Drugs 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 230000008217 follicular development Effects 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 230000004185 hypothalamic-pituitary-gonadal axis Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 229960005337 lysine hydrochloride Drugs 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000006109 methionine Nutrition 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229940079464 niacin 50 mg Drugs 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 102000037983 regulatory factors Human genes 0.000 description 1
- 108091008025 regulatory factors Proteins 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 208000017443 reproductive system disease Diseases 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000012711 vitamin K3 Nutrition 0.000 description 1
- 239000011652 vitamin K3 Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 235000015099 wheat brans Nutrition 0.000 description 1
- 229940050168 zinc lactate Drugs 0.000 description 1
- 235000000193 zinc lactate Nutrition 0.000 description 1
- 239000011576 zinc lactate Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
- A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/163—Sugars; Polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/174—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/189—Enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/30—Feeding-stuffs specially adapted for particular animals for swines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/064—Saccharomycetales, e.g. baker's yeast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
- A61K36/296—Epimedium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/36—Caryophyllaceae (Pink family), e.g. babysbreath or soapwort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/533—Leonurus (motherwort)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01001—Alpha-amylase (3.2.1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01004—Cellulase (3.2.1.4), i.e. endo-1,4-beta-glucanase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01008—Endo-1,4-beta-xylanase (3.2.1.8)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01011—Dextranase (3.2.1.11)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01015—Polygalacturonase (3.2.1.15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Polymers & Plastics (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Animal Husbandry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Physiology (AREA)
- Biomedical Technology (AREA)
- Birds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明公开了一种提高母猪生产性能的药物、其制备方法及应用,属于兽药技术领域。本发明提高母猪生产性能的药物由以下组分按重量份数制备而成:维生素2~10份、植物提取物4~15份、酶制剂2~6份、氨基酸2~6份、微生态制剂1~5份、甘露寡糖1~6份。本发明的药物给药方便,高效,安全,无残留;可有效预防母猪产程过长;促进母猪产后恢复;增加排卵,延长母猪使用年限;使用本发明的药物还可以促进母猪乳腺发育和乳汁分泌,改善奶水品质;对母猪使用本发明药物的同时,还能提高母猪的产仔质量,泌乳期使用本发明药物,不仅能够提高仔猪的成活率,还能保证仔猪健康快速地生长。
Description
技术领域
本发明属于兽药技术领域,具体涉及一种提高母猪生产性能的药物、其制备方法及应用。
背景技术
近年来,随着我国养猪业集约化程度的不断提高,在母猪的饲养管理过程中存在泌乳不足和便秘的问题,而母猪的营养状况直接决定了母猪的泌乳质量,进而影响到母猪的繁殖性能和仔猪的生长性能。在规模化养殖中,母猪的繁殖障碍也频现,母猪繁殖生产效率显著下降,已成为限制规模化养猪生产效率和良种快速扩繁的瓶颈。母猪繁殖障碍主要是指不良饲养、繁殖及疫病等因素导致的母猪长期不发情、屡配不孕、流产、死胎、母猪使用年限短等现象。在生产中,繁殖障碍不仅引起母猪大量过早淘汰,而且导致母猪空怀天数即母猪非工作日增加,使得猪场生产效率大幅下降。
造成母猪繁殖障碍有多重因素,除了饲料营养外,还有疫病、管理、繁殖技术本身等,但是饲料品质是重要的基础保障。由于母猪的正常生产寿命远长于肥猪,使得饲料有害物质更容易造成体内蓄积,一些饲料毒素会直接影响母猪的生殖系统机能;另外,母猪处在不同生理阶段对营养的需求变化差异较大,在生产中很容易出现饲料配制不合理导致的营养不良问题,以造成机体免疫力下降,使得对一些繁殖障碍疾病如蓝耳病、猪瘟、伪狂犬等更加易感。由于母猪的正常生殖机能依靠生殖内分泌多种激素的调控,如果不能及早采取生产措施进行合理饲养管理,一旦造成严重的繁殖障碍后将难以在短时间内恢复正常的繁殖性能。
针对上述情况,目前通常采用向母猪饲料中添加复合添加剂的方法来改善母猪繁殖性能。2014年5月14日中国发明专利公布号CN103783293A公开了“含有机微量元素的生物饲料组合物及其应用、母猪专用复合预混料、母猪专用饲料”,该生物饲料组合物包括有机微量元素和酵母代谢产物;有机微量元素包括甘氨酸铜、富马酸亚铁、乳酸锌、蛋氨酸锰、酵母硒和烟酸铬。其改善母猪繁殖力的原理是酵母代谢产物可促进各微量元素协同作用的发挥,提高微量元素的利用率,提高母猪的抗病力和免疫力,调节母猪繁殖相关的激素代谢。2014年3月5日中国发明专利公布号CN103609885A公开了“一种母猪饲料添加剂”,该饲料添加剂采用玉米蛋白粉、鱼骨粉、食盐、复合维生素、鱼油、叶酸、磷酸氢钙、赖氨酸、蛋氨酸、硫酸亚铁、L-乳酸、富马酸混合制备成颗粒制剂,以供给母猪生长充分的营养,增强母猪免疫力,加速其对饲料的吸收,有效改善母猪繁殖性能。两者共同点是强化母猪的营养,提高营养物质的吸收利用率,不同点是强化的营养物质不同,添加量不同。
目前常用促性腺激素治疗,但存在着价格昂贵、副作用大等问题。
发明内容
本发明针对现代养殖场母猪发情率低、受孕率低,产仔数少,产仔后母猪奶水不足等问题,提供了一种提高母猪生产性能的药物,本发明的技术方案如下:
一种提高母猪生产性能的药物,由以下组分按重量份数制备而成:维生素2~10份、植物提取物4~15份、酶制剂2~6份、氨基酸2~6份、微生态制剂1~5份、甘露寡糖1~6份;
所述维生素是由维生素A乙酸酯、维生素D3、dl-α-生育酚乙酸酯、维生素E、维生素B2、叶酸、生物素按1~3∶2~5∶1~5∶1~3∶2~5∶1~3∶1~5的重量比混合而成;
所述植物提取物是由黄芪、艾叶、淫羊藿、益母草、当归、王不留行、枳壳按1~10∶2~5∶1~5∶3~7∶2~8∶2~6∶1~5的重量比制备而成;
所述的酶制剂是由中温淀粉酶、蛋白酶、纤维素酶、果胶酶、β-葡聚糖酶、木聚糖酶按8~15∶1~4∶3~5∶2~3∶2~5∶1~4的重量比混合而成;
所述的氨基酸是由赖氨酸、缬氨酸、蛋氨酸、苯丙氨酸按5~8∶1~3∶2~6∶1~5的重量比混合而成;
所述的微生态制剂是由地衣芽孢杆菌、枯草芽孢杆菌、酵母菌中的一种或多种。
在上述方案的基础上,所述植物提取物的制备方法为:
①称取各中药组分,加入10倍重量水,煮沸提取2h,滤过;
②向上述滤渣中加入8倍重量水,煮沸提取2h,滤过;
③合并①②中的滤液,浓缩至1/6重量的稠膏状;
④将③中的稠膏真空干燥,粉碎,过80目筛,得植物提取物。
在上述方案的基础上,所述提高母猪生产性能的药物,由以下组分按重量份数制备而成:维生素2~4份、植物提取物10~15份、酶制剂2~3份、氨基酸2~3份、微生态制剂1~3份、甘露寡糖1~5份;
所述维生素是由维生素A乙酸酯、维生素D3、dl-α-生育酚乙酸酯、维生素E、维生素B2、叶酸、生物素按2~3∶1~3∶2~5∶2~3∶2~4∶2~3∶1~5的重量比混合而成;
所述植物提取物是由黄芪、艾叶、淫羊藿、益母草、当归、王不留行、枳壳按6~10∶2~3∶2~5∶3~4∶2~5∶5~6∶1~2的重量比制备而成;
所述的酶制剂是由中温淀粉酶、蛋白酶、纤维素酶、果胶酶、β-葡聚糖酶、木聚糖酶按10~12∶1~2∶3~5∶2~3∶2~5∶1~2的重量比混合而成;
所述的氨基酸是由赖氨酸、缬氨酸、蛋氨酸、苯丙氨酸按5~6∶1~3∶2~3∶1~2的重量比混合而成;
所述的微生态制剂是由地衣芽孢杆菌、枯草芽孢杆菌、酵母菌按2~8∶3~10∶2~5的重量比混合而成。
在上述方案的基础上,所述提高母猪生产性能的药物,由以下组分按重量份数制备而成:维生素3份、植物提取物10份、酶制剂2份、氨基酸3份、微生态制剂1份、甘露寡糖2份;
所述维生素是由维生素A乙酸酯、维生素D3、dl-α-生育酚乙酸酯、维生素E、维生素B2、叶酸、生物素按3∶1∶5∶2∶3∶3∶1的重量比混合而成;
所述植物提取物是由黄芪、艾叶、淫羊藿、益母草、当归、王不留行、枳壳按6∶3∶5∶4∶5∶5∶2的重量比制备而成;
所述的酶制剂是由中温淀粉酶、蛋白酶、纤维素酶、果胶酶、β-葡聚糖酶、木聚糖酶按12∶1∶3∶2∶5∶2的重量比混合而成;
所述的氨基酸是由赖氨酸、缬氨酸、蛋氨酸、苯丙氨酸按照5∶3∶2∶1的比例混合而成;
所述的微生态制剂是由地衣芽孢杆菌、枯草芽孢杆菌、酵母菌按2∶10∶3的重量比制备而成。
在上述方案的基础上,所述提高母猪生产性能的药物,由以下组分按重量份数制备而成:维生素2份、植物提取物12份、酶制剂2份、氨基酸3份、微生态制剂2份、甘露寡糖1份;
所述维生素是由维生素A乙酸酯、维生素D3、dl-α-生育酚乙酸酯、维生素E、维生素B2、叶酸、生物素按3∶2∶2∶2∶4∶2∶3的重量比混合而成;
所述植物提取物是由黄芪、艾叶、淫羊藿、益母草、当归、王不留行、枳壳按10∶2∶5∶3∶2∶6∶1的重量比制备而成;
所述的酶制剂是由中温淀粉酶、蛋白酶、纤维素酶、果胶酶、β-葡聚糖酶、木聚糖酶按10∶2∶5∶3∶2∶1的重量比混合而成;
所述的氨基酸是由赖氨酸、缬氨酸、蛋氨酸、苯丙氨酸按照5∶1∶3∶2的比例混合而成;
所述的微生态制剂是由地衣芽孢杆菌、枯草芽孢杆菌、酵母菌按3∶5∶2的重量比混合而成。
在上述方案的基础上,所述提高母猪生产性能的药物,由以下组分按重量份数制备而成:维生素4份、植物提取物15份、酶制剂3份、氨基酸2份、微生态制剂3份、甘露寡糖5份;
所述维生素是由维生素A乙酸酯、维生素D3、dl-α-生育酚乙酸酯、维生素E、维生素B2、叶酸、生物素按2∶3∶4∶3∶2∶2∶5的重量比混合而成;
所述植物提取物是由黄芪、艾叶、淫羊藿、益母草、当归、王不留行、枳壳按8∶3∶2∶4∶2∶5∶1的重量比制备而成;
所述的酶制剂是由中温淀粉酶、蛋白酶、纤维素酶、果胶酶、β-葡聚糖酶、木聚糖酶按10∶1∶3∶2∶3∶2的重量比混合而成;
所述的氨基酸是由赖氨酸、缬氨酸、蛋氨酸、苯丙氨酸按照6∶2∶2∶1的比例混合而成;
所述的微生态制剂是由地衣芽孢杆菌、枯草芽孢杆菌、酵母菌按8∶3∶5的重量比混合而成。
在上述方案的基础上,所述提高母猪生产性能的药物的制备方法,步骤如下:
(1)称取维生素、植物提取物、氨基酸、甘露寡糖,粉碎过80目筛;
(2)称取酶制剂、微生态制剂单独过80目筛;
(3)将(1)和(2)各组分混合均匀,即得。
上述方法制备的药物的应用于提高母猪产仔性能、提高泌乳质量、促进母猪断奶后再发情配种、缩短空怀期、提高哺乳仔猪的生长性能。
一种提高母猪产仔性能、提高泌乳质量、促进母猪断奶后再发情配种、缩短空怀期的饲料,是在饲料中添加上述方法制备的药物,添加量为重量份数1%。
一种提高哺乳仔猪生长性能的方法,是在为仔猪哺乳的母猪饲料中添加上述方法制备的药物,添加量为重量份数1%。
地衣芽孢杆菌,生产厂家:山东蔚蓝生物科技有限公司;
枯草芽孢杆菌,生产厂家:潍坊益昊生物技术有限公司,商品编号:014;
酵母菌,生产厂家:山东蔚蓝生物科技有限公司。
本发明的有益效果
本发明的药物给药方便,高效,安全,无残留;可有效预防母猪产程过长;促进母猪产后恢复;增加排卵,延长母猪使用年限;使用本发明的药物还可以促进母猪乳腺发育和乳汁分泌,改善奶水品质;对母猪使用本发明药物的同时,还能提高母猪的产仔质量,泌乳期使用本发明药物,不仅能够提高仔猪的成活率,还能保证仔猪健康快速地生长。
本发明药物功效:1、补气养血通经下乳,有效缩短产程,促进泌乳,改善乳汁品质,提高哺乳仔猪均匀度及断奶量。2、减轻母猪生产过程中疼痛感,避免子宫痉挛,促进母猪产后恢复。3、有效减少哺乳母猪断奶掉膘问题,及断奶后迟迟不发情,缩短空怀期。4、预防母猪的生殖炎症和仔猪腹泻的发生,提高机体免疫力及抗病力,降低生殖性疾病发病率。
本发明药物中王不留行活血通经、消肿止痛、催生下乳,益母草活血调经、消肿、祛瘀,当归补血活血、调经止痛、润肠通便,艾叶温经、止血、安胎,淫羊藿补肾阳、强筋骨为君药;黄芪补气固表、提高免疫、促进新陈代谢为臣药;枳壳理气宽中、行滞消胀为佐药;七药合用,共奏活血、调经、祛瘀、催生、下乳、补肾阳之治则。
在本发明植物提取物的补气养血通经下乳,清热解毒抗菌消炎,活血化瘀消痈散肿,脱毒固表增强免疫功能的基础上,配以维生素来促进脏器恢复,提高母猪生理功能、繁育功能、免疫功能和仔猪的成活率。本发明药物中的酶制剂是复合蛋白酶、脂肪酶等内源酶制剂,各酶之间相互协同,共同降解、促进营养物质的消化吸收,提高母猪产奶量和仔猪出生窝量。本发明药物中的氨基酸为蛋白脂肪等的合成提供组件,提升乳脂、乳蛋白的含量;促进乳腺急性发育,产前一周促进α-乳球蛋白合成,生成乳糖合成酶,促进乳糖的合成,提高乳腺上皮细胞渗透压,促进乳汁分泌。微生态制剂可调节母猪和仔猪肠道微生物菌群的平衡,抑制致病菌的繁殖,在促进产后母猪身体恢复的同时,减少仔猪断奶后腹泻的产生,促进营养物质的消化吸收,增加生长速度。在甘露寡糖存在下,微生态制剂能够最大化的发挥作用,在干扰肠道病原菌的定殖的同时,减少动物肠道病原微生物,提高机体免疫力,促进免疫器官的发育,增强抗病和抗应激能力;此外,妊娠后期母猪日粮中补充甘露寡糖(MOS)对初乳中免疫球蛋白的组成有利,甘露寡糖可提高初乳抗体水平,从而提高仔猪的免疫力,减少仔猪疾病的发生。本发明药物添加到断奶后的母猪饲料中,促进母猪原始卵泡发育,刺激产生性激素,卵泡发育成熟,并反馈至下丘脑-垂体-性腺轴系,解除相关调控因子的抑制,促使腺垂体分泌FSH和LH,进一步促进卵泡的成熟排放,提高母猪的发情率,缩短空怀期。
综上,本发明药物绿色安全高效,可显著提高母猪泌乳量和乳脂率,减少仔猪腹泻,增加仔猪整齐度及断奶窝重,同时促进排卵,提高断奶后配种率。提高母猪的整体健康水平,增加母猪的免疫力,有效延长母猪的使用年限。促进母猪有效排卵量,增加产健仔数量。
具体实施方式
在本发明中所使用的术语,除非有另外说明,一般具有本领域普通技术人员通常理解的含义。
下面结合具体实施例,并参照数据进一步详细的描述本发明。以下实施例只是为了举例说明本发明,而非以任何方式限制本发明的范围。
实施例1
一种提高母猪生产性能的药物,是由以下重量份的组分制备而成:
维生素2份、植物提取物12份、酶制剂2份、氨基酸3份、微生态制剂2份、甘露寡糖1份;
所述维生素是由维生素A乙酸酯、维生素D3、dl-α-生育酚乙酸酯、维生素E、维生素B2、叶酸、生物素按3∶2∶2∶2∶4∶2∶3的重量比混合而成;
所述植物提取物是由黄芪、艾叶、淫羊藿、益母草、当归、王不留行、枳壳按10∶2∶5∶3∶2∶6∶1的重量比制备而成;
所述植物提取物的制备方法为:
①称取各中药组分,加入10倍重量水,煮沸提取2h,滤过;
②向上述滤渣中加入8倍重量水,煮沸提取2h,滤过;
③合并①②中的滤液,浓缩至1/6重量的稠膏状;
④将③中的稠膏真空干燥,粉碎,过80目筛,得植物提取物。
所述的酶制剂是由中温淀粉酶、蛋白酶、纤维素酶、果胶酶、β-葡聚糖酶、木聚糖酶按10∶2∶5∶3∶2∶1的重量比混合而成;
所述的氨基酸是由赖氨酸、缬氨酸、蛋氨酸、苯丙氨酸按照5∶1∶3∶2的比例混合而成;
所述的微生态制剂是由地衣芽孢杆菌、枯草芽孢杆菌、酵母菌按3∶5∶2的重量比混合而成。
上述提高母猪生产性能的药物的制备方法,步骤如下:
(1)称取维生素、植物提取物、氨基酸、甘露寡糖,粉碎过80目筛;
(2)称取酶制剂、微生态制剂单独过80目筛;
(3)将(1)和(2)各组分混合均匀,即得。
实施例2
一种提高母猪生产性能的药物,是由以下重量份的组分制备而成:
维生素3份、植物提取物10份、酶制剂2份、氨基酸3份、微生态制剂1份、甘露寡糖2份;
所述维生素是由维生素A乙酸酯、维生素D3、dl-α-生育酚乙酸酯、维生素E、维生素B2、叶酸、生物素按3∶1∶5∶2∶3∶3∶1的重量比混合而成;
所述植物提取物是由黄芪、艾叶、淫羊藿、益母草、当归、王不留行、枳壳按6∶3∶5∶4∶5∶5∶2的重量比制备而成;
植物提取物的制备方法同实施例1。
所述的酶制剂是由中温淀粉酶、蛋白酶、纤维素酶、果胶酶、β-葡聚糖酶、木聚糖酶按12∶1∶3∶2∶5∶2的重量比混合而成;
所述的氨基酸是由赖氨酸、缬氨酸、蛋氨酸、苯丙氨酸按照5∶3∶2∶1的比例混合而成;
所述的微生态制剂是由地衣芽孢杆菌、枯草芽孢杆菌、酵母菌按2∶10∶3的重量比制备而成。
上述提高母猪生产性能的药物的制备方法,同实施例1。
实施例3
一种提高母猪生产性能的药物,是由以下重量份的组分制备而成:
维生素4份、植物提取物15份、酶制剂3份、氨基酸2份、微生态制剂3份、甘露寡糖5份;
所述维生素是由维生素A乙酸酯、维生素D3、dl-α-生育酚乙酸酯、维生素E、维生素B2、叶酸、生物素按2∶3∶4∶3∶2∶2∶5的重量比混合而成;
所述植物提取物是由黄芪、艾叶、淫羊藿、益母草、当归、王不留行、枳壳按8∶3∶2∶4∶2∶5∶1的重量比制备而成;
植物提取物的制备方法同实施例1。
所述的酶制剂是由中温淀粉酶、蛋白酶、纤维素酶、果胶酶、β-葡聚糖酶、木聚糖酶按10∶1∶3∶2∶3∶2的重量比混合而成;
所述的氨基酸是由赖氨酸、缬氨酸、蛋氨酸、苯丙氨酸按照6∶2∶2∶1的比例混合而成;
所述的微生态制剂是由地衣芽孢杆菌、枯草芽孢杆菌、酵母菌按8∶3∶5的重量比混合而成。
上述提高母猪生产性能的药物的制备方法,同实施例1。
实施例4
一种提高母猪生产性能的药物,是由以下重量份的组分制备而成:
维生素10份、植物提取物4份、酶制剂6份、氨基酸6份、微生态制剂5份、甘露寡糖6份;
所述维生素是由维生素A乙酸酯、维生素D3、dl-α-生育酚乙酸酯、维生素E、维生素B2、叶酸、生物素按1∶5∶1∶1∶5∶1∶2的重量比混合而成;
所述植物提取物是由黄芪、艾叶、淫羊藿、益母草、当归、王不留行、枳壳按1∶5∶1∶7∶8∶2∶3的重量比制备而成;
植物提取物的制备方法同实施例1。
所述的酶制剂是由中温淀粉酶、蛋白酶、纤维素酶、果胶酶、β-葡聚糖酶、木聚糖酶按8∶1∶3∶3∶2∶3的重量比混合而成;
所述的氨基酸是由赖氨酸、缬氨酸、蛋氨酸、苯丙氨酸按照8∶3∶6∶5的比例混合而成;
所述的微生态制剂是由地衣芽孢杆菌、枯草芽孢杆菌按8∶5的重量比混合而成。
上述提高母猪生产性能的药物的制备方法,同实施例1。
实施例5
一种提高母猪生产性能的药物,是由以下重量份的组分制备而成:
维生素8份、植物提取物6份、酶制剂5份、氨基酸4份、微生态制剂4份、甘露寡糖3份;
所述维生素是由维生素A乙酸酯、维生素D3、dl-α-生育酚乙酸酯、维生素E、维生素B2、叶酸、生物素按2∶4∶3∶3∶3∶3∶4的重量比混合而成;
所述植物提取物是由黄芪、艾叶、淫羊藿、益母草、当归、王不留行、枳壳按4∶4∶3∶5∶5∶4∶5的重量比制备而成;
植物提取物的制备方法同实施例1。
所述的酶制剂是由中温淀粉酶、蛋白酶、纤维素酶、果胶酶、β-葡聚糖酶、木聚糖酶按15∶4∶4∶2∶4∶4的重量比混合而成;
所述的氨基酸是由赖氨酸、缬氨酸、蛋氨酸、苯丙氨酸按照7∶1∶2∶4的比例混合而成;
所述的微生态制剂是3重量份的枯草芽孢杆菌。
上述提高母猪生产性能的药物的制备方法,同实施例1。
一、药效试验
1.1试验分组
1.1.1实施例1的药物;
1.1.2实施例2的药物;
1.1.3实施例3的药物;
1.1.4实施例4的药物;
1.1.5实施例5的药物;
1.1.6实施例2中不添加维生素制备的药物;
1.1.7实施例2中不添加植物提取物制备的药物;
1.1.8实施例2中不添加酶制剂制备的药物;
1.1.9实施例2中不添加氨基酸制备的药物;
1.1.10实施例2中不添加微生态制剂制备的药物;
1.1.11实施例2中不添加甘露寡糖制备的药物;
1.1.12空白对照组。
1.2动物试验设计
试验地点:山东省诸城市某牧业有限公司养殖场。
试验时间:试验从2016年8月10日开始至10月28日结束。
试验猪的选择及分组:选择以往繁殖正常的3~4胎次、体重和体况相近,配种妊娠85d的长大二元经产母猪144头,按随机区组将144头母猪分为12组,每组均为12头,于母猪妊娠85d开始进入正式试验,至断奶(断奶日龄21d)后发情间隔期10d,试验期61d。
试验期的饲养管理:试验前猪舍进行消毒,其中,1~11组的母猪在基础日粮(本场按照母猪六阶段科学饲养法,母猪妊娠85d开始至断奶均采用哺乳母猪饲料,妊娠85d至产后3d限制饲喂量,产后4d哺乳期实行自由采食)中分别添加1.1各组中的药物,添加量为1%,其中添加1.1.1~1.1.5药物的组记为实施例1~实施例5组,添加1.1.6~1.1.11组药物的组记为对照组1~对照组6,第12组基础日粮中不添加任何药物,记为空白对照组;上述各组母猪妊娠期均采用半限位栏饲养(每栏4头),哺乳期采用产床单体饲养,两组试验猪妊娠期、哺乳期及所带哺乳仔猪的饲养管理方法一致,仔猪出生后2~3d补铁,5~7d开始补料,统一于21d断奶。
1.3检测指标:(1)母猪产仔性能:以窝为单位记录窝产仔猪数、活仔猪数、初生个体重、断奶个体重、初生窝重、断奶窝重;(2)母猪泌乳性能与乳质:总泌乳力、日均泌乳力、乳蛋白、乳脂、乳糖、总固形物、非脂乳固体;(3)母猪断奶后再发情配种:1~7d内发情率、8~14d内发情率、受胎率、断奶再发情间隔时间。
1.4结果分析
试验数据采用SAS17.0统计软件进行单因素方差分析,用Duncan氏多重比较检验,结果用平均数±标准差表示。
1.4.1试验基础日粮组成与营养水平(见表1)
表1、基础日粮组成及营养水平
原料 | 怀孕后期 | 泌乳期 | 空怀期 |
玉米 | 48.5 | 47 | 47 |
小麦 | 17 | 20 | 21 |
麸皮 | 19 | 8 | 6 |
豆粕 | 12.3 | 21.1 | 22.1 |
石粉 | 1 | 0.7 | 0.7 |
磷酸氢钙 | 1 | 0.9 | 0.9 |
食盐 | 0.34 | 0.3 | 0.3 |
赖氨酸盐酸盐 | 0.16 | 0.15 | 0.15 |
氯化胆碱(50%) | 0.1 | 0.1 | 0.1 |
无机微量元素预混料 | 0.5 | 0.5 | 0.5 |
有机微量元素预混料 | 0.5 | 0.5 | 0.5 |
豆油 | 0 | 1 | 1 |
维生素预混料 | 0.03 | 0.03 | 0.03 |
抗氧化剂 | 0.03 | 0.03 | 0.03 |
复合酶制剂 | 0.04 | 0.04 | 0.04 |
合计 | 100 | 100 | 100 |
营养水平 | |||
消化能DE(MJ/kg) | 13.05 | 13.42 | 13.76 |
粗蛋白CP/% | 14.2 | 16.92 | 17.92 |
钙Ca/% | 0.70 | 0.70 | 0.70 |
磷P/% | 0.63 | 0.60 | 0.59 |
有效磷AP/% | 0.33 | 0.32 | 0.32 |
赖氨酸Lys/% | 0.73 | 0.92 | 0.95 |
蛋氨酸Met/% | 0.20 | 0.23 | 0.26 |
注:母猪用维生素预混料每kg全料含:维生素A12000IU,维生素D32000IU,维生素E120IU,维生素K30.5mg,生物素0.25mg,尼克酸50mg,泛酸40mg,核黄素2.5mg,维生素B12mg,维生素B61mg,维生素B1210μg。
1.4.2各组母猪产仔性能(见表2)
表2各组母猪产仔性能
由表2可知,对妊娠后期的母猪使用本发明药物,窝均总产仔猪数虽略有差别,但影响不大,各组之间不存在显著差异;实施例1~5的窝均产活仔猪数显著高于对照组2、3、5和空白对照组,对照组1、4、6与其他各组差异不大;实施例1~5组初生个体重显著高于各对照组,对照组1~6的初生个体重显著高于空白对照组;实施例1~3组的初生窝重显著高于对照组1、4、6,极显著高于对照组2、3、5和空白对照组,与实施例4、5组无显著差异;使用本发明的药物可显著增加产活仔猪数和仔猪的出生体重,实施例2组药物效果最佳。
1.4.3各组哺乳仔猪生长性能(见表3)
表3各组哺乳仔猪生长性能
由表3可知,对哺乳期的母猪使用本发明的药物,仔猪21d断乳个体重、21d断乳窝重、断乳窝增重、平均日增重实施例1~5组均显著高于其他各对照组;各组母猪带仔数相差不大,断乳仔猪数实施例1~5组均显著高于其他各对照组;使用本发明实施例1~5的药物,仔猪的育成率也显著高于其他各组;可见本发明药物能显著增加哺乳仔猪的生长性能,其中本发明实施例2组的药效最佳。
1.4.4各药物对母猪泌乳力及初乳成分的影响(见表4)
表4各药物对母猪泌乳力及初乳成分的影响
由表4可知:使用本发明的药物可以增加哺乳期母猪的泌乳量,使用本发明实施例1~5药物的母猪总泌乳力、日均泌乳力、乳蛋白、乳脂、乳糖、总固形物和非乳固体的含量显著高于其他对照组,这说明本发明的药物能够提高母猪乳汁的质量,其中本发明实施例2的药物效果最佳。
1.4.5各组药物对母猪发情配种的影响(见表5)
表5各组药物对母猪发情配种的影响
由表5可知,本发明实施例1~5制备的药物能够缩+短母猪的发情期,提高情期的受胎率,其中,本发明实施例2的药物效果最好。
二、各组药物对不同类别母猪的生产性能的影响
2.1试验设计
在山东诸城市多个猪场进行多次试饲喂试验,试验采用对比试验设计,并分为后备母猪、初产母猪、经产母猪三部分,每部分分试验组和对照组,试验对象为不发情或发情不好的体重大小、健康状况基本一致的后备母猪、初产母猪、经产母猪各20头,试验组饲喂本发明实施例2所制备的药物,饲喂方法:将药物按照1%比例添加到基础日粮中自由采食,饲喂时间:7天,对照组饲喂常规母猪用配合饲料,饲料中不添加任何药物,其他试验条件一致。
2.2指标测定
2.2.1血浆中FSH和LH含量的测定
分别于试验前一天和试验第7天,对试验母猪和对照组母猪静脉采血,采用酶联免疫法(ELISA)分别检测母猪血浆中FSH和LH的含量。
2.2.2统计母猪生产性能
统计后备母猪、初产母猪和经产母猪试验组和对照组的平均发情率、平均受胎率、平均产仔头数和平均每日泌乳量。
2.3试验结果
2.3.1血浆中FSH和LH含量的测定(见表6)
表6血浆中FSH和LH含量的测定
由表6可知,在饲料中添加本发明药物后,均提高初产母猪及经产母猪血浆中FSH和LH含量,且差异显著;也增加未配种后备母猪血浆中LH含量,差异显著;FSH含量差异不显著。说明本发明药物能够促使腺垂体分泌FSH和LH,进一步促进卵泡的成熟排放,提高母猪的发情率,缩短空怀期。
2.3.2各组药物对不同类别母猪的生产性能的影响(见表7)
表7各组药物对不同类别母猪的生产性能的影响
试验结果表明:1、发情率:后备母猪试验组比对照组提高了17.23%,初产母猪试验组比对照组提高了22.32%,经产母猪试验组比对照组提高了15.13%;2受胎率:后备母猪试验组比对照组提高了17.34%,初产母猪试验组比对照组提高了18.79%,经产母猪试验组比对照组提高了19.13%,3、产仔数:初产母猪试验组比对照组提高了4.9头,经产母猪试验组比对照组提高了8.44头;4、泌乳量:初产母猪试验组比对照组每日提高了3.4kg,经产母猪试验组比对照组每日提高了6.0kg。通过上述试验结果分析可知,本发明的药物明显促进了母猪的发情率和受胎率,产仔数和泌乳量也显著提高,本发明的药物增强了母猪的生产性能和泌乳功。
三、药理学毒性试验
3.1试验方法
选取体重为18~22g的ICR鼠120只,经3天适应性饲养后,随机均分为6组(雌雄各半),实施例1组~实施例5组和空白对照组,每组各20只;空白对照组灌胃生理盐水,实施例1组~实施例5组分别将各实施例制备的药物溶于水中灌服,各组药物添加量为0.1g/mL,0.3mL/次,一天3次,连续7天。
3.2测定指标及方法
(1)临床症状观察:每日观察试验鼠的精神状态、饮食情况,每日记录发病死亡情况。
(2)病理学观察:对于死亡鼠进行剖检观察内脏变化。
(3)生长指标观察:对试验鼠进行定期称重;试验结束,扑杀鼠称量体重、脏器重脏器指数测定:剖检大鼠,取心脏、脾脏、肝脏、肾脏、睾丸、卵巢,称重,按照下式计算脏器指数:脏器指数=脏器重/体重×100。
(4)肝脏功能变化观察:试验结束后,扑杀鼠,采取血液分离血清,测定AST、ALT。
3.3数据处理与分析
所有采集数据采用Excel软件进行前期处理,然后用SPSS 19.0进行统计分析,LSD进行多重比较,结果采用平均值±标准差表示。
3.3.1临床症状观察
对照组和试验组鼠,精神状态和饮食欲、对外界反应能力未见明显的异常。各组鼠均未出现发病和死亡情况。
3.3.2病理学观察:对照组和试验组,鼠扑杀后进行剖检眼观未见观察内脏器官明显的病理变化。
3.3.3生长指标观察:试验结束,扑杀鼠称量体重、脏器重分析见表8。
表8各脏器指数分析
分组 | 肝脏指数 | 心脏指数 | 肾脏指数 | 肺脏指数 | 脾脏指数 |
实施例1组 | 52.33±1.38a | 4.81±0.11a | 13.59±0.27a | 6.65±0.41a | 4.57±0.45a |
实施例2组 | 52.24±1.42a | 4.65±0.22a | 13.53±0.24a | 6.69±0.40a | 4.55±0.51a |
实施例3组 | 52.27±1.47a | 4.76±0.18a | 13.56±0.26a | 6.63±0.44a | 4.52±0.54a |
实施例4组 | 52.19±1.23a | 4.53±0.14a | 13.49±0.27a | 6.58±0.47a | 4.47±0.49a |
实施例5组 | 52.22±1.35a | 4.62±0.25a | 13.51±0.29a | 6.60±0.43a | 4.50±0.51a |
空白对照组 | 51.46±1.51a | 4.51±0.29a | 13.44±0.25a | 6.51±0.45a | 4.45±0.50a |
注:同列肩标相同字母表示差异不显著(P>0.05),肩标不同小写字母表示差异显著(P<0.05)。
由表8可知,各脏器指数分析,各试验组与对照组之间无显著性差异(P>0.05)。
3.3.4肝脏功能变化观察
试验结束后,扑杀鼠,采取血液分离血清,测定AST(谷草转氨酶)、ALT(谷丙转氨酶)见表9。
表9 AST和ALT测定
分组 | 总数 | ALT | AST |
实施例1组 | 20 | 34.78±2.12a | 106.85±5.02a |
实施例2组 | 20 | 34.88±2.05a | 106.71±4.94a |
实施例3组 | 20 | 34.83±2.00a | 106.79±5.11a |
实施例4组 | 20 | 34.72±2.09a | 106.65±4.98a |
实施例5组 | 20 | 34.75±2.03a | 106.77±4.84a |
空白对照组 | 20 | 34.66±1.98a | 106.89±5.17a |
注:同列肩标相同字母表示差异不显著(P>0.05),肩标不同小写字母表示差异显著(P<0.05)。
由表9可知,各组数据与空白对照组相比差异不显著,都处于正常范围内。
3.4长期毒性试验资料
根据实施例2制备的本发明药物,15g/kg、80g/kg给1月龄ICR鼠连续灌胃给药1个月,动物的皮毛、肤色、摄食、活动、尿、便等均无异常;动物的血常规、肝、肾功能等血液生化指标和动物的主要脏器指数均在正常范围,且正常动力无差异;病理组织学检查表明,心、肝、脾、肺、肾、肾上腺、气管、睾丸、卵巢等重要脏器无病理改变。停药两周后检查以上各项指标均无明显毒性反应,表明无蓄积毒性。
以上所述,仅是本发明的较佳实施例而已,并非是对本发明作其它形式的限制,任何熟悉本专业的技术人员可能利用上述揭示的技术内容加以变更或改型为等同变化的等效实施例。但是凡是未脱离本发明技术方案内容,依据本发明的技术实质对以上实施例所作的任何简单修改、等同变化与改型,仍属于本发明技术方案的保护范围。
Claims (10)
1.一种提高母猪生产性能的药物,其特征在于:由以下组分按重量份数制备而成:维生素2~10份、植物提取物4~15份、酶制剂2~6份、氨基酸2~6份、微生态制剂1~5份、甘露寡糖1~6份;
所述维生素是由维生素A乙酸酯、维生素D3、dl-α-生育酚乙酸酯、维生素E、维生素B2、叶酸、生物素按1~3∶2~5∶1~5∶1~3∶2~5∶1~3∶1~5的重量比混合而成;
所述植物提取物是由黄芪、艾叶、淫羊藿、益母草、当归、王不留行、枳壳按1~10∶2~5∶1~5∶3~7∶2~8∶2~6∶1~5的重量比制备而成;
所述的酶制剂是由中温淀粉酶、蛋白酶、纤维素酶、果胶酶、β-葡聚糖酶、木聚糖酶按8~15∶1~4∶3~5∶2~3∶2~5∶1~4的重量比混合而成;
所述的氨基酸是由赖氨酸、缬氨酸、蛋氨酸、苯丙氨酸按5~8∶1~3∶2~6∶1~5的重量比混合而成;
所述的微生态制剂是由地衣芽孢杆菌、枯草芽孢杆菌、酵母菌中的一种或多种。
2.根据权利要求1所述提高母猪生产性能的药物,其特征在于:所述植物提取物的制备方法为:
①称取各中药组分,加入10倍重量水,煮沸提取2h,滤过;
②向上述滤渣中加入8倍重量水,煮沸提取2h,滤过;
③合并①②中的滤液,浓缩至1/6重量的稠膏状;
④将③中的稠膏真空干燥,粉碎,过80目筛,得植物提取物。
3.根据权利要求1或2所述提高母猪生产性能的药物,其特征在于:由以下组分按重量份数制备而成:维生素2~4份、植物提取物10~15份、酶制剂2~3份、氨基酸2~3份、微生态制剂1~3份、甘露寡糖1~5份;
所述维生素是由维生素A乙酸酯、维生素D3、dl-α-生育酚乙酸酯、维生素E、维生素B2、叶酸、生物素按2~3∶1~3∶2~5∶2~3∶2~4∶2~3∶1~5的重量比混合而成;
所述植物提取物是由黄芪、艾叶、淫羊藿、益母草、当归、王不留行、枳壳按6~10∶2~3∶2~5∶3~4∶2~5∶5~6∶1~2的重量比制备而成;
所述的酶制剂是由中温淀粉酶、蛋白酶、纤维素酶、果胶酶、β-葡聚糖酶、木聚糖酶按10~12∶1~2∶3~5∶2~3∶2~5∶1~2的重量比混合而成;
所述的氨基酸是由赖氨酸、缬氨酸、蛋氨酸、苯丙氨酸按5~6∶1~3∶2~3∶1~2的重量比混合而成;
所述的微生态制剂是由地衣芽孢杆菌、枯草芽孢杆菌、酵母菌按2~8∶3~10∶2~5的重量比混合而成。
4.根据权利要求3所述提高母猪生产性能的药物,其特征在于:由以下组分按重量份数制备而成:维生素3份、植物提取物10份、酶制剂2份、氨基酸3份、微生态制剂1份、甘露寡糖2份;
所述维生素是由维生素A乙酸酯、维生素D3、dl-α-生育酚乙酸酯、维生素E、维生素B2、叶酸、生物素按3∶1∶5∶2∶3∶3∶1的重量比混合而成;
所述植物提取物是由黄芪、艾叶、淫羊藿、益母草、当归、王不留行、枳壳按6∶3∶5∶4∶5∶5∶2的重量比制备而成;
所述的酶制剂是由中温淀粉酶、蛋白酶、纤维素酶、果胶酶、β-葡聚糖酶、木聚糖酶按12∶1∶3∶2∶5∶2的重量比混合而成;
所述的氨基酸是由赖氨酸、缬氨酸、蛋氨酸、苯丙氨酸按照5∶3∶2∶1的比例混合而成;
所述的微生态制剂是由地衣芽孢杆菌、枯草芽孢杆菌、酵母菌按2∶10∶3的重量比制备而成。
5.根据权利要求3所述提高母猪生产性能的药物,其特征在于:由以下组分按重量份数制备而成:维生素2份、植物提取物12份、酶制剂2份、氨基酸3份、微生态制剂2份、甘露寡糖1份;
所述维生素是由维生素A乙酸酯、维生素D3、dl-α-生育酚乙酸酯、维生素E、维生素B2、叶酸、生物素按3∶2∶2∶2∶4∶2∶3的重量比混合而成;
所述植物提取物是由黄芪、艾叶、淫羊藿、益母草、当归、王不留行、枳壳按10∶2∶5∶3∶2∶6∶1的重量比制备而成;
所述的酶制剂是由中温淀粉酶、蛋白酶、纤维素酶、果胶酶、β-葡聚糖酶、木聚糖酶按10∶2∶5∶3∶2∶1的重量比混合而成;
所述的氨基酸是由赖氨酸、缬氨酸、蛋氨酸、苯丙氨酸按照5∶1∶3∶2的比例混合而成;
所述的微生态制剂是由地衣芽孢杆菌、枯草芽孢杆菌、酵母菌按3∶5∶2的重量比混合而成。
6.根据权利要求3所述提高母猪生产性能的药物,其特征在于:由以下组分按重量份数制备而成:维生素4份、植物提取物15份、酶制剂3份、氨基酸2份、微生态制剂3份、甘露寡糖5份;
所述维生素是由维生素A乙酸酯、维生素D3、dl-α-生育酚乙酸酯、维生素E、维生素B2、叶酸、生物素按2∶3∶4∶3∶2∶2∶5的重量比混合而成;
所述植物提取物是由黄芪、艾叶、淫羊藿、益母草、当归、王不留行、枳壳按8∶3∶2∶4∶2∶5∶1的重量比制备而成;
所述的酶制剂是由中温淀粉酶、蛋白酶、纤维素酶、果胶酶、β-葡聚糖酶、木聚糖酶按10∶1∶3∶2∶3∶2的重量比混合而成;
所述的氨基酸是由赖氨酸、缬氨酸、蛋氨酸、苯丙氨酸按照6∶2∶2∶1的比例混合而成;
所述的微生态制剂是由地衣芽孢杆菌、枯草芽孢杆菌、酵母菌按8∶3∶5的重量比混合而成。
7.根据权利要求1~6任一项所述提高母猪生产性能的药物的制备方法,其特征在于:步骤如下:
(1)称取维生素、植物提取物、氨基酸、甘露寡糖,粉碎过80目筛;
(2)称取酶制剂、微生态制剂单独过80目筛;
(3)将(1)和(2)各组分混合均匀,即得。
8.根据权利要求7所述方法制备的药物的应用,其特征在于:用于提高母猪产仔性能、提高泌乳质量、促进母猪断奶后再发情配种、缩短空怀期、提高哺乳仔猪的生长性能。
9.一种提高母猪产仔性能、提高泌乳质量、促进母猪断奶后再发情配种、缩短空怀期的饲料,其特征在于:在饲料中添加权利要求7所述方法制备的药物,添加量为重量份数1%。
10.一种提高哺乳仔猪生长性能的方法,其特征在于:在为仔猪哺乳的母猪饲料中添加权利要求7所述方法制备的药物,添加量为重量份数1%。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711391548.3A CN108079284B (zh) | 2017-12-21 | 2017-12-21 | 一种提高母猪生产性能的药物、其制备方法及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711391548.3A CN108079284B (zh) | 2017-12-21 | 2017-12-21 | 一种提高母猪生产性能的药物、其制备方法及应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108079284A true CN108079284A (zh) | 2018-05-29 |
CN108079284B CN108079284B (zh) | 2021-03-16 |
Family
ID=62177890
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201711391548.3A Active CN108079284B (zh) | 2017-12-21 | 2017-12-21 | 一种提高母猪生产性能的药物、其制备方法及应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108079284B (zh) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108887497A (zh) * | 2018-06-28 | 2018-11-27 | 南宁学院 | 一种提高母猪生产性能的中药添加剂及其制备方法 |
CN109007353A (zh) * | 2018-07-27 | 2018-12-18 | 普定县景凤种养殖专业合作社 | 一种用于增加母猪泌乳的饲料添加剂 |
CN109925429A (zh) * | 2019-04-16 | 2019-06-25 | 江西正邦动物保健品有限公司 | 一种改善母猪繁殖性能的中药复方制剂及其制备方法 |
CN114042096A (zh) * | 2021-12-10 | 2022-02-15 | 湖南德诺健康产业集团有限公司 | 一种改善母猪繁殖性能的植物提取物复方产品及其生产工艺和应用 |
CN114601050A (zh) * | 2022-03-17 | 2022-06-10 | 重庆市畜牧技术推广总站 | 一种提高仔猪免疫力的母猪饲料添加剂及使用方法 |
CN115176917A (zh) * | 2022-08-03 | 2022-10-14 | 武汉谷歌香农牧饲料科技有限公司 | 一种母猪哺乳期复合预混合饲料及其制备方法 |
CN116898896A (zh) * | 2023-08-30 | 2023-10-20 | 福建益昕葆生物制药有限公司 | 一种提高哺乳期母猪泌乳量的中药组合物及其制备和应用 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1903279A (zh) * | 2005-07-29 | 2007-01-31 | 天津天士力现代中药研究开发有限公司 | 一种枳壳药材的提取分离方法 |
CN101999545A (zh) * | 2010-12-01 | 2011-04-06 | 北京资源亚太饲料科技有限公司 | 一种哺乳母猪配合饲料及其制备方法 |
CN102763781A (zh) * | 2012-07-31 | 2012-11-07 | 河南光泰动物药业有限公司 | 提高哺乳母猪生产性能的营养剂及其制备方法 |
CN103053852A (zh) * | 2013-01-23 | 2013-04-24 | 郑州宏展饲料添加剂有限公司 | 一种哺乳母猪6%预混料及使用该预混料配制成的小麦型日粮 |
CN103652492A (zh) * | 2013-12-16 | 2014-03-26 | 双胞胎(集团)股份有限公司 | 提高泌乳量和增强免疫力的哺乳母猪饲料添加剂 |
CN105166340A (zh) * | 2015-07-22 | 2015-12-23 | 广西富来康饲料有限公司 | 一种提高仔猪断奶重的母猪饲料 |
CN106974113A (zh) * | 2017-05-04 | 2017-07-25 | 谢又华 | 一种饲料添加剂及其制备方法、应用和相应饲料 |
-
2017
- 2017-12-21 CN CN201711391548.3A patent/CN108079284B/zh active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1903279A (zh) * | 2005-07-29 | 2007-01-31 | 天津天士力现代中药研究开发有限公司 | 一种枳壳药材的提取分离方法 |
CN101999545A (zh) * | 2010-12-01 | 2011-04-06 | 北京资源亚太饲料科技有限公司 | 一种哺乳母猪配合饲料及其制备方法 |
CN102763781A (zh) * | 2012-07-31 | 2012-11-07 | 河南光泰动物药业有限公司 | 提高哺乳母猪生产性能的营养剂及其制备方法 |
CN103053852A (zh) * | 2013-01-23 | 2013-04-24 | 郑州宏展饲料添加剂有限公司 | 一种哺乳母猪6%预混料及使用该预混料配制成的小麦型日粮 |
CN103652492A (zh) * | 2013-12-16 | 2014-03-26 | 双胞胎(集团)股份有限公司 | 提高泌乳量和增强免疫力的哺乳母猪饲料添加剂 |
CN105166340A (zh) * | 2015-07-22 | 2015-12-23 | 广西富来康饲料有限公司 | 一种提高仔猪断奶重的母猪饲料 |
CN106974113A (zh) * | 2017-05-04 | 2017-07-25 | 谢又华 | 一种饲料添加剂及其制备方法、应用和相应饲料 |
Non-Patent Citations (1)
Title |
---|
迅达康兽药: "产诺康(畜用)奶多仔壮母猪月子更轻松http://www.soocom.com.cn/show-564-37216-1.html", 《百度》 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108887497A (zh) * | 2018-06-28 | 2018-11-27 | 南宁学院 | 一种提高母猪生产性能的中药添加剂及其制备方法 |
CN109007353A (zh) * | 2018-07-27 | 2018-12-18 | 普定县景凤种养殖专业合作社 | 一种用于增加母猪泌乳的饲料添加剂 |
CN109925429A (zh) * | 2019-04-16 | 2019-06-25 | 江西正邦动物保健品有限公司 | 一种改善母猪繁殖性能的中药复方制剂及其制备方法 |
CN114042096A (zh) * | 2021-12-10 | 2022-02-15 | 湖南德诺健康产业集团有限公司 | 一种改善母猪繁殖性能的植物提取物复方产品及其生产工艺和应用 |
CN114601050A (zh) * | 2022-03-17 | 2022-06-10 | 重庆市畜牧技术推广总站 | 一种提高仔猪免疫力的母猪饲料添加剂及使用方法 |
CN115176917A (zh) * | 2022-08-03 | 2022-10-14 | 武汉谷歌香农牧饲料科技有限公司 | 一种母猪哺乳期复合预混合饲料及其制备方法 |
CN116898896A (zh) * | 2023-08-30 | 2023-10-20 | 福建益昕葆生物制药有限公司 | 一种提高哺乳期母猪泌乳量的中药组合物及其制备和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN108079284B (zh) | 2021-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108079284A (zh) | 一种提高母猪生产性能的药物、其制备方法及应用 | |
CN101268802B (zh) | 哺乳母猪饲料 | |
CN101869224B (zh) | 用于提高哺乳母猪泌乳性能的饲料添加剂及其制备方法 | |
CN108094320A (zh) | 一种母猪模式化饲喂方法及其妊娠期饲料 | |
CN106819482A (zh) | 提高哺乳母猪生产性能的无抗生素饲料及其制备方法 | |
CN105192433A (zh) | 一种围产期母猪专用全价配合饲料 | |
CN108450672B (zh) | 一种母猪围产期配合饲料及其制备方法 | |
CN105614099B (zh) | 一种改善怀孕母猪健康和提高怀孕母猪繁殖性能的功能性清洁日粮 | |
CN108371252A (zh) | 一种促进母猪产后炎症康复和催乳的中药发酵饲料添加剂及其制备方法和应用 | |
CN108244369A (zh) | 一种泌乳母猪专用微量元素发酵饲料及其制备方法 | |
CN105614094A (zh) | 一种怀孕母猪专用发酵饲料原料制剂及其制备方法和应用 | |
CN102613403A (zh) | 一种奶牛围产后期精补料及其制备方法 | |
CN108740456A (zh) | 一种泌乳母猪用饲料及其制备方法 | |
CN106509440A (zh) | 经产母猪保健饲料添加剂 | |
CN106819471A (zh) | 一种新丹系母猪妊娠期破碎饲料及其制备方法 | |
CN108077622B (zh) | 一种提高母猪生产性能的添加剂及其制备方法和包含其的混合饲料 | |
CN106509441A (zh) | 一种无抗生素种母猪预混合饲料 | |
CN104705528A (zh) | 一种母猪专用复合维生素发酵中草药制剂及其制备方法和应用 | |
CN109497311A (zh) | 一种哺乳母猪合生素剂及其制备方法 | |
CN107469056A (zh) | 一种发酵型益母生化散、制备方法及应用 | |
CN105124162A (zh) | 一种用于抗热应激的复方制剂及其制备方法 | |
CN109329560A (zh) | 解决妊娠母猪便秘和生产性能的饲料添加剂及其制备方法 | |
CN106804904A (zh) | 一种中草药的奶牛饲料添加剂 | |
CN109362963A (zh) | 一种提高断奶窝重的泌乳母猪用复合预混合饲料及其制备方法和应用 | |
CN106578484A (zh) | 一种中草药哺乳期母猪饲料添加剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20211213 Address after: 250000 Jinan agricultural high tech Development Zone, Shandong Province Patentee after: SHANDONG XUNDAKANG BIOTECHNOLOGY CO.,LTD. Patentee after: Shandong xundakang Veterinary Medicine Co., Ltd Address before: 250300 Jinan agricultural high tech Development Zone, Shandong Province Patentee before: SHANDONG XUNDAKANG BIOTECHNOLOGY CO.,LTD. |